- CAG repeats code for glutamine; expanded repeats create toxic polyglutamine tracts.
- Pathogenic repeat lengths vary by disease, e.g., >36 repeats cause Huntington’s disease.
- Anticipation can lengthen repeats in each generation, resulting in earlier onset.
- PCR with capillary electrophoresis measures most repeats; Southern blotting is used for very large expansions.
- Allele‑specific therapies such as antisense oligonucleotides are in clinical trials.
What are CAG repeats and why do they matter?
CAG repeats are short DNA sequences where the nucleotides cytosine‑adenine‑guanine occur consecutively. In human genes, the number of CAG copies can expand beyond normal limits, producing an abnormal polyglutamine tract that leads to several neurodegenerative disorders. The most well‑known condition caused by an expanded CAG repeat is Huntington’s disease.
How does a CAG repeat affect protein structure?
Each CAG codon codes for the amino acid glutamine. When a gene contains many CAG repeats, the resulting protein harbors a long stretch of glutamine residues, called a polyglutamine (polyQ) tract. PolyQ tracts above a disease‑specific threshold cause the protein to misfold, aggregate, and interfere with normal cellular functions.
Which diseases are linked to expanded CAG repeats?
Over 20 inherited disorders are classified as CAG‑repeat expansion diseases. The most frequently cited are:
- Huntington’s disease (HD)
- Spinocerebellar ataxia type 1 (SCA1)
- Dentatorubral‑pallidoluysian atrophy (DRPLA)
- Spinal and bulbar muscular atrophy (SBMA, also called Kennedy’s disease)
What are the typical repeat ranges for these conditions?
| Disease | Normal CAG Range | Pathogenic Range | Typical Age of Onset |
|---|---|---|---|
| Huntington’s disease | 10–35 | 36–120+ | 30–50 years |
| Spinocerebellar ataxia 1 | 4–35 | 38–84 | 20–40 years |
| DRPLA | 6–34 | 35–100 | 10–30 years |
| SBMA (Kennedy’s) | 9–33 | 38–62 | 30–60 years |
How is CAG repeat length measured?
Clinical laboratories use polymerase chain reaction (PCR) followed by capillary electrophoresis to size the repeat region. For very large expansions (>100 repeats) that PCR cannot amplify, Southern blotting or long‑read sequencing technologies are employed. Results are reported as the exact number of repeats on each allele.
Can a person have a borderline CAG repeat count?
Yes. Individuals with repeat numbers in the high‑normal or “intermediate” range (e.g., 36–39 for Huntington’s disease) may never develop symptoms but can pass an expanded allele to offspring, where the repeat may further increase—a phenomenon called anticipation.
What are the clinical implications of a positive CAG test?
A confirmed pathogenic CAG expansion provides a definitive molecular diagnosis, guiding prognosis, family planning, and eligibility for clinical trials. However, the test does not predict exact disease severity or progression speed; other genetic modifiers and environmental factors play roles.
Are there treatments that target the CAG repeat itself?
Current therapeutic strategies focus on reducing the toxic polyQ protein or its downstream effects. Approaches under investigation include antisense oligonucleotides (ASOs) that selectively silence the mutant allele, CRISPR‑based excision of the repeat, and small molecules that improve protein folding.
How does anticipation influence family counseling?
Anticipation describes the tendency of CAG repeats to lengthen in successive generations, leading to earlier onset and more severe disease. Genetic counselors explain this risk, discuss predictive testing for at‑risk adults, and recommend reproductive options such as pre‑implantation genetic diagnosis (PGD).
What are the ethical considerations of predictive CAG testing?
Predictive testing raises issues of psychological impact, insurance discrimination, and privacy. In many jurisdictions, legislation (e.g., the U.S. Genetic Information Nondiscrimination Act) protects individuals, but counselors still emphasize informed consent and post‑test support.
What recent research advances have emerged for CAG‑related disorders?
In 2023, a phase II trial of the ASO drug tominersen showed modest slowing of Huntington’s disease progression, renewing interest in allele‑specific silencing. Additionally, long‑read nanopore sequencing now enables accurate sizing of ultra‑large repeats, improving diagnostic certainty for rare CAG diseases.
How might future technologies improve CAG detection?
Machine‑learning models that integrate repeat length, epigenetic marks, and transcriptomic data are being developed to predict individual disease trajectories. Combined with wearable neuro‑monitoring, these tools could personalize clinical care for patients with CAG expansions.
Summary
CAG repeats are a simple three‑base DNA motif whose expansion creates toxic polyglutamine proteins, leading to a spectrum of neurodegenerative diseases. Accurate measurement, careful counseling, and emerging gene‑targeted therapies are central to managing affected individuals.
Frequently Asked Questions
What is the normal range of CAG repeats in the HTT gene?
In the HTT gene that causes Huntington’s disease, normal alleles contain 10 to 35 CAG repeats. Individuals with 36 or more repeats are at risk for developing the disease, with earlier onset seen at higher repeat counts.
Can a person with an intermediate CAG repeat develop symptoms later in life?
People with intermediate repeats (typically 36‑39 for Huntington’s) may remain asymptomatic, but they can transmit larger expansions to children, who may then develop symptoms earlier. Ongoing monitoring is recommended.
How is CAG repeat testing performed in a clinical lab?
Clinical labs amplify the repeat region by PCR and size the fragments using capillary electrophoresis. For very large expansions, Southern blotting or long‑read sequencing is used to obtain an accurate repeat count.
What therapeutic options target the mutant CAG allele?
Experimental treatments include antisense oligonucleotides that silence the mutant transcript, CRISPR‑based excision of the repeat, and small molecules that promote proper protein folding. None are yet approved for routine use.
Is genetic discrimination a concern for people tested for CAG expansions?
Yes, but laws such as the U.S. Genetic Information Nondiscrimination Act (GINA) protect against health‑insurance and employment discrimination. Counselors still discuss privacy and potential stigma before testing.